

Comparative Survival and Cost-Effectiveness of Advanced Therapies for End-Stage Heart Failure

Elisa F. Long, PhD; Gary W. Swain, MD, MBA; Abeel A. Mangi, MD

Background—Treatment options for end-stage heart failure include inotrope-dependent medical therapy, orthotopic heart transplantation (OHT), left ventricular assist device (LVAD) as destination therapy or bridge to transplant.

Methods and Results—We developed a state-transition model to simulate 4 treatment options and associated morbidity and mortality. Transition probabilities, costs, and utilities were estimated from published sources. Calculated outcomes included survival, quality-adjusted life-years, and incremental cost-effectiveness. Sensitivity analyses were performed on model parameters to test robustness. Average life expectancy for OHT-eligible patients is estimated at 1.1 years, with 39% surviving to 1 year. OHT with a median wait time of 5.6 months is estimated to increase life expectancy to 8.5 years, and costs <\$100 000/quality-adjusted life-year gained, relative to inotrope-dependent medical therapy. Bridge to transplant-LVAD followed by OHT further is estimated to increase life expectancy to 12.3 years, for \$226 000/quality-adjusted life-year gained versus OHT. Among OHT-ineligible patients, mean life expectancy with inotrope-dependent medical therapy is estimated at 9.4 months, with 26% surviving to 1 year. Patients who instead received destination therapy-LVAD are estimated to live 4.4 years on average from extrapolation of recent constant hazard rates beyond the first year. This strategy costs \$202 000/quality-adjusted life-year gained, relative to inotrope-dependent medical therapy. Patient's age, time on wait list, and costs associated with care influence outcomes.

Conclusions—Under most scenarios, OHT prolongs life and is cost effective in eligible patients. Bridge to transplant-LVAD is estimated to offer >3.8 additional life-years for patients waiting ≥ 6 months, but does not meet conventional cost-effectiveness thresholds. Destination therapy-LVAD significantly improves life expectancy in OHT-ineligible patients. However, further reductions in adverse events or improved quality of life are needed for destination therapy-LVAD to be cost effective. (*Circ Heart Fail.* 2014;7:470-478.)

Key Words: cost-benefit analysis ■ transplantation

Heart failure afflicts >5 million Americans,¹ with 700 000 people newly diagnosed each year.² In 2013, heart failure cost our healthcare system >\$32 billion and is expected to double by 2030.² A considerable proportion of hospitalized patients with heart failure have inotrope-dependent stage D heart failure³⁻⁵ and experience a 1-year survival rate of only 25%.⁶⁻⁸ The nationwide cost of index hospitalizations alone for orthotopic heart transplantation (OHT) and left ventricular assist device (LVAD) implantation approached \$1 billion in 2009.⁹

Clinical Perspective on p 478

OHT is considered the definitive therapy for patients with inotrope-dependent stage D heart failure, with 1-year survival exceeding 85%.^{10,11} Median survival for all OHT recipients is currently 10 years, increasing to 13 years conditional on surviving the first year.¹⁰ More than 3500 people are currently listed for OHT, with a median wait-list time of 5 to 6 months,¹² although only 2200 OHT operations are performed

annually in the United States, in part attributable to limited donor availability.^{10,13}

Randomized clinical trials involving patients with stage D heart failure have demonstrated improvements in survival among transplant-ineligible patients undergoing LVAD implantation as destination therapy (DT). The Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH) trial showed a 48% reduction in risk of death in LVAD patients when compared with patients receiving inotrope-dependent medical therapy (IDMT).⁶ Heartmate-II investigators subsequently showed that patients implanted with continuous-flow LVADs achieved a 54% reduction in risk of death when compared with patients implanted with earlier LVADs used in the REMATCH trial.¹⁴ Further analysis has shown a 1-year survival approaching 80% among patients receiving DT-LVAD.¹⁵ Patients who undergo LVAD implantation as a bridge to transplant (BTT) obtain 1-year survival rates nearly as high as OHT.¹⁶ The presence

Received July 9, 2013; accepted February 14, 2014.

From Decisions, Operations & Technology Management, UCLA Anderson School of Management, Los Angeles, CA (E.F.L.); Department of Surgery, Icahn School of Medicine at Mount Sinai, New York, NY (G.W.S.); and Section of Cardiac Surgery, Department of Surgery, Yale School of Medicine, New Haven, CT (A.A.M.).

The Data Supplement is available at <http://circheartfailure.ahajournals.org/lookup/suppl/doi:10.1161/CIRCHEARTFAILURE.113.000807/-/DC1>.

Correspondence to Abeel A. Mangi, MD, Section of Cardiac Surgery, Yale School of Medicine, Boardman 204, 330 Cedar St, New Haven, CT 06510. E-mail abeel.mangi@yale.edu

© 2014 American Heart Association, Inc.

Circ Heart Fail is available at <http://circheartfailure.ahajournals.org>

DOI: 10.1161/CIRCHEARTFAILURE.113.000807

of an LVAD does not seem to impact survival after OHT, although this is currently under debate.^{17,18}

Although ≈1800 LVADs were implanted in the United States in 2012—more than double the number implanted in 2008. Although these predictions are challenging to establish, it has been estimated that far more patients might be eligible for LVAD or OHT in the United States alone.^{15,19} Given the substantial costs of both procedures,⁹ the economic impact of such strategies deserves consideration. In this analysis, we evaluated the health benefits, survival, costs, and comparative cost-effectiveness of treatment strategies for patients with inotrope-dependent stage D heart failure.

Methods

Study Design

We developed a novel decision-analytic model (Figure 1) to estimate survival and costs among patients with inotrope-dependent stage D heart failure under different treatment strategies. Among transplant-ineligible patients, we compared IDMT with DT-LVAD. For transplant-eligible patients, we evaluated IDMT, OHT, BTT-LVAD, and DT-LVAD. Although these patients would likely receive a heart transplant once a suitable organ becomes available, we included

DT-LVAD as a hypothetical scenario to assess whether conditions exist where it may be preferable to receive DT-LVAD in lieu of BTT or OHT. In addition, the DT-LVAD strategy characterizes patients who start as BTT-LVAD but become ineligible for OHT and thereby convert to a DT-LVAD platform by default. Sensitivity analyses on parameters were performed to test model assumptions. Additional details are provided in the Appendix in the Data Supplement. The study was approved by the Human Investigations Committee of the Human Research Protection Program at Yale University.

A health state-transition model with 1-month cycle lengths was created to simulate a cohort of 20000 hypothetical patients. Each month, patients transition between health states based on the risk of developing condition-specific complications or dying, with transition probabilities were derived from survival rates reported in the literature (Appendix Table I in the Data Supplement). Probability values were modeled as time varying, where appropriate, to more accurately reflect clinical course. Age-related mortality rates were estimated from Centers for Disease Control life tables,²⁰ with a base-case initial patient age of 50 years (Appendix Table II in the Data Supplement). All analyses were conducted using a lifetime horizon. The model was implemented in TreeAge Pro 2013 Software.

Survival Rates

We calibrated the model to published survival rates for ≤4 years follow-up in LVAD patients and 7 years for transplant patients




Figure 1. Decision-analytic model diagram for treatment of end-stage heart failure. The initial square node represents a decision point where a treatment regimen is chosen. The open circle nodes represent chance events, and the M circle nodes represent the health states. Patients can transition among health states according to specified transition probabilities. Patients may die from any health state based on the associated mortality rate or from age-related mortality. The model assigns costs and quality-of-life values to each health state. The simulation then calculates the average lifetime costs and quality-adjusted life-years of each treatment regimen, based on a cohort of 20000 patients. LVAD indicates left ventricular assist device.

Table 1. Survival, Complication Rates, Costs, and Quality-of-Life Inputs to Model

Survival Probability	Freedom From Complications	Costs (2012 \$)	Quality-of-Life Factor	
IDMT, OHT eligible ²¹	Stroke ¹⁵	Monthly IDMT care ^{7,22}	IDMT ^{7,23}	0.53
6 mo	1 mo	12 mo before death	LVAD month 1 ²³	0.51
1 y	3 mo	12–24 mo before death	LVAD months 2+ ¹⁵	0.72
2 y	1 y	24+ mo before death	Heart transplant ²³	0.76
IDMT, OHT ineligible ^{6,7}	2 y	LVAD index hospitalization ^{9,24}	Stroke ²⁵	0.68
6 mo	3 y	Monthly post-LVAD care ^{26–28}	Gastrointestinal bleed*	0.60
1 y	Driveline infection ¹⁵	Months 1–12	Driveline infection*	0.60
2 y	6 mo	Months 12+	Transplant rejection*	0.76
LVAD, OHT eligible ^{15,29}	1 y	OHT index hospitalization ⁹	CAV*	0.76
6 mo	2 y	Monthly post-OHT care ^{26,27}	Renal dysfunction ³⁰	0.57
1 y	Gastrointestinal bleed ^{31–33}	Months 1–12	Skin malignancy ³⁴	0.65
2 y	6 mo	Months 12+	Lymphoma/other malignancies ^{34,35}	0.55
LVAD, OHT ineligible ^{15,29}	1 y	End-of-life care ⁷		
6 mo	2 y	Acute stroke ³⁶		
1 y	Pump failure ¹⁵	Monthly poststroke care ³⁶		
2 y	6 mo	Gastrointestinal bleed ³⁷		
Post-heart transplant ^{10,11,22}	1 y	Driveline infection ²⁴		
6 mo	2 y	CAV*		
1 y	Transplant rejection ¹⁰	Monthly post-CAV care*		
2 y	1 y	Renal dysfunction initial care ³⁸		
3 y	2 y	Monthly renal dysfunction care ³⁸		
7 y	4 y	Skin malignancy ³⁹		
	Malignancy ¹⁰	Monthly post-skin malignancy care ³⁹		
	1 y	Lymphoma/other malignancies ³⁹		
	5 y	Months 1–24		
	10 y	Months 24+		
	CAV ¹⁰			
	1 y			
	3 y			
	7 y			
	Renal dysfunction ¹⁰			
	1 y			
	3 y			
	7 y			

CAV indicates cardiac allograft vasculopathy; IDMT, inotrope-dependent medical therapy; LVAD, left ventricular assist device; and OHT, orthotopic heart transplant.
*Value determined by expert opinion and Yale-New Haven Hospital data.

(Table 1). Beyond these time horizons, we extrapolated the appropriate mortality rates to project future survival; however, the model may be updated to reflect newer estimates as data become available.

Contemporary survival rates for LVAD patients were obtained from the Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS), which enrolled 6885 LVAD patients between 2006 and 2012.¹⁵ LVAD survival at 6, 12, and 24 months was 88%, 82%, and 74%, respectively. We assumed a higher mortality rate in the first month postimplantation and increased rates of serious complications which contribute to higher mortality for the first 12 months postimplantation. Beyond 12 months, we assumed a constant monthly mortality hazard rate based on a similar observation in INTERMACS from 12 to 48 months.¹⁵ Our model closely matches INTERMACS data for patients with continuous-flow LVADs in the current era (Appendix Figure I in the Data Supplement).^{15,29} We also assumed 5% lower survival at 1 year for DT patients ineligible for OHT.¹⁵

OHT survival was obtained from the International Society of Heart and Lung Transplantation (ISHLT), where post-transplant survival rates for years 1 through 7 were 86%, 82%, 79%, 76%, 73%, 69%, and 66%, respectively.¹⁰ We calibrated transition probabilities to closely match ISHLT data (Appendix Figure II in the Data Supplement); we assumed a higher mortality rate for the first 12 months post-transplantation, but then a constant monthly mortality rate thereafter. Similar post-transplant mortality rates were used for patients who received IDMT or LVAD pretransplantation.^{11,16–18} The median wait-list time to receive a heart in the United States was 5.6 months based on the Scientific Registry of Transplant Recipients (SRTR).¹² In our model, we randomly generated a different wait-list time for each patient, such that the median wait time is 5.6 months. Under a constant hazard rate of an organ becoming available, this implies that 77% of patients receive a heart within 1 year.

Estimates of survival among patients receiving IDMT vary widely, in part because of differences in baseline patient characteristics. The REMATCH trial demonstrated survival rates of 23% at 1 year and 8% at 2 years among OHT-ineligible patients, which formed the basis for our survival assumptions in this population.^{6,7} Survival estimates for OHT-eligible patients on IDMT were based on an analysis of United Network for Organ Sharing status 1A and 1B patients who did not receive an LVAD while awaiting OHT. Survival rates of 63%, 40%, and 16% at 6 months, 1 year, and 2 years, respectively, were assumed in our analysis of OHT-eligible IDMT patients.²¹

In addition to estimating survival curves based on our simulation, we calculated the mean life expectancy associated with each treatment modality. We simulated each patient's health state transitions according to the mortality and complication rates until death. We then averaged across all patients to compute the mean life expectancy.

Complication Rates

Our model captured the development of specific clinical complications (Figure 1) and accounted for the associated costs and quality-of-life decrements. After LVAD implantation, common complications include stroke, gastrointestinal bleeding, driveline infection, or pump failure requiring device replacement.⁴⁰ Among heart transplant recipients, organ rejection, cardiac allograft vasculopathy, renal dysfunction, and malignancy are possible complications. BTT-LVAD patients may experience complications resulting from either LVAD or OHT. All complication rates were validated against published estimates (Appendix Table III in the Data Supplement).

Quality of Life and Costs

Outcomes estimated for each strategy were average life expectancy, quality-adjusted life-years (QALYs), lifetime costs, and incremental cost-effectiveness ratios (ICERs) relative to the next-best strategy in terms of cost per life-year gained or QALY gained. We adhered to recommendations for cost-effectiveness studies by using a societal perspective and discounting both costs and QALYs at a 3% annual rate.⁴¹

Quality-of-life estimates were obtained from literature review (Table 1). Each health state was associated with a quality-of-life value ranging from 0 to 1, where 0 represents death and 1 represents ideal health. QALYs were computed by aggregating the total time spent in each health state and applying the appropriate utility weight.

The costs of each treatment intervention, associated complications, and follow-up health care were estimated (Table 1). All costs were updated to 2012 US dollars using the medical care component of the consumer price index.⁴² Direct medical costs associated with the index hospitalization for LVAD implantation and OHT were based on the Heartmate-II DT trial²⁴ and the Nationwide Inpatient Sample.⁹ Professional fees were derived from a prior analysis of Medicare claims for patients undergoing LVAD implantation in 2008.⁷ Direct

costs for repeat hospitalizations and outpatient care were derived from 3674 patient-months from June 2011 to May 2013 at Yale-New Haven Hospital, which included 30 LVAD, 32 OHT, and 32 IDMT patients. These costs were reconciled with costs of post-LVAD implant, post-OHT care, and IDMT from previous reports.^{7,22,26-28}

Results

Base-Case Analysis

Based on a simulation of 20000 patients with inotrope-dependent stage D heart failure aged 50 years (Figure 2), average life expectancy for OHT-eligible patients on IDMT was 1.1 years, with a 1-year survival rate of 40%, consistent with published estimates.⁴³ Similar patients who immediately receive OHT live for an additional 13.8 years on average, with a 5-year survival rate of 74%. Our model results are similar to post-transplantation survival estimates reported by ISHLT.^{10,22} However, because patients typically face a waiting period before a heart becomes available, we calculated life expectancy while accounting for this wait-list time. Given a median OHT wait-list time of 5.6 months, life expectancy is 8.5 years, with a 5-year survival rate of 44%, assuming patients received IDMT while awaiting OHT. Patients with similar transplant wait-list times who instead receive BTT-LVAD live an additional 12.3 years on average, slightly less than patients who are immediately transplanted (13.8 years) because of LVAD-associated complications and surgical mortality risk (Table 2).

Among patients who are OHT ineligible, the average life expectancy with IDMT was 9.4 months with a 1-year survival of 26%, consistent with prior reports.⁶ Alternatively, from extrapolation of recent constant hazard rates beyond the first year, DT-LVAD quintuples life expectancy to 4.4 years in OHT-ineligible patients, generating 1-year and 2-year survival rates of 78% and 62%, respectively, consistent with reports in the literature.²⁹

Cost-Effectiveness Analysis

Under the base-case scenario, OHT costs ≈\$97000 per QALY gained or \$54000 per life-year gained relative to IDMT in OHT-eligible patients (Figure 3). If a patient from this cohort receives BTT-LVAD, the ICER exceeds \$226000 per QALY gained relative to OHT, primarily attributable to the substantial inpatient hospital costs associated with both




Figure 2. Model-projected survival during 5 years. Each line corresponds to the fraction of a cohort surviving over time. Immediate heart transplantation (dashed) and transplantation following a median wait time of 5.6 months (solid) are both shown. Bridge to transplant-left ventricular assist device (LVAD) assumes a median wait of 5.6 months following LVAD implantation. Inotrope-dependent medical therapy (IDMT) or destination therapy-LVAD among patients who are transplant eligible (solid) or ineligible (dashed) are also shown. OHT indicates orthotopic heart transplant.

Table 2. Model Results and Cost-Effectiveness Analysis

Strategy	Lifetime Costs, (\$)*	5-Year Survival, %†	Life Expectancy, y	QALYs*	Incremental Cost-Effectiveness Ratio, ‡ \$/life-year	Incremental Cost-Effectiveness Ratio, ‡ \$/QALY
Heart transplant ineligible						
Inotrope-dependent medical therapy	112 600	0	0.78	0.41
LVAD destination therapy	593 000	32	4.42	2.79	131 800	201 600
Heart transplant eligible						
Inotrope-dependent medical therapy	130 300	1	1.13	0.58
Heart transplant						
Immediate	802 200	74	13.76	7.67	53 200	94 800
Wait-list 5.6 mo	529 000	44	8.48	4.70	54 300	96 900
Wait-list 12 mo	405 700	31	6.18	3.41	54 500	97 300
LVAD bridge to transplant						
Immediate	1 025 500	71	13.12	7.32	Dominated	Dominated
Wait-list 5.6 mo	1 011 900	65	12.29	6.83	126 700	226 300
Wait-list 12 mo	978 000	59	11.41	6.40	109 400	191 400

LVAD indicates left ventricular assist device; and QALY, quality-adjusted life-year.

*Lifetime costs and QALYs are discounted at a 3% annual rate.

†Results are based on a simulation of 20 000 hypothetical patients aged 50 years.

‡Incremental cost-effectiveness ratios for LVAD destination therapy and heart transplant are relative to inotrope-dependent medical therapy, and LVAD bridge to transplant is relative to heart transplant.

procedures. In the hypothetical scenario where an OHT-eligible patient underwent LVAD implantation with the intention of later undergoing OHT, but for whatever reason converted to DT-LVAD, this strategy would cost \$175 000 per QALY gained but would confer fewer QALYs than OHT or BTT-LVAD. In OHT-ineligible patients, DT-LVAD carries an ICER of \$202 000 per QALY gained or \$132 000 per life-year gained, compared with medical therapy.

Sensitivity Analyses

Age

Our base-case simulation considered 50-year-old patients. As patients age, all cohorts experience a decrease in life expectancy driven by age-related mortality (Figure 4), resulting in worsening cost-effectiveness. We projected 75-year-old LVAD patients' survival rates of 78% (1 year), 65%

(2 years), and 52% (3 years). INTERMACS reports survival rates of 75%, 63%, and 54% for patients aged ≥70 years.⁴⁴ Among 75-year-old heart transplant recipients, we projected post-transplant survival rates of 86%, 80%, 73%, 67%, and 60% at years 1 through 5, respectively, compared with 80%, 76%, 72%, 67%, and 66% reported by ISHLT for patients aged ≥70 years.¹⁰ Modest survival rate differences may arise because both INTERMACS and ISHLT pool survival data for all patients aged >70 years.

In OHT-eligible patients, OHT costs <\$100 000 per QALY gained relative to IDMT in patients aged <63 years, whereas BTT-LVAD exceeds \$200 000 per QALY gained relative to OHT across all ages, assuming a median wait-list time of 5.6 months.

Among OHT-ineligible patients, DT-LVAD exceeds \$150 000 per QALY gained relative to IDMT even for patients in their 40s. Some debate exists about whether DT-LVAD




Figure 3. Cost-effectiveness of end-stage heart failure therapy options. Discounted lifetime costs and quality-adjusted life-years (QALYs) are shown for each treatment regimen. The cost-effectiveness frontier (black line) represents those strategies that are most economically efficient. Among orthotopic heart transplant (OHT)-ineligible patients (open squares), destination therapy-left ventricular assist device (LVAD) is compared with inotrope-dependent medical therapy (IDMT). All other points (closed squares) correspond to OHT-eligible patients. The cost-effectiveness of OHT is relative to IDMT, and bridge to transplant (BTT)-LVAD is relative to OHT.




Figure 4. Sensitivity analysis of key model parameters. Sensitivity analysis graphs illustrate the impact on life expectancy and cost-effectiveness (\$ per quality-adjusted life-year [QALY] gained) given variations in key model parameters: patient's age (A and B), median wait time for heart transplantation (C and D), and the monthly probability of death with inotrope-dependent medical therapy (IDMT; E and F). Patients are categorized as orthotopic heart transplant (OHT) eligible (solid lines) or OHT ineligible (dashed lines). LVAD indicates left ventricular assist device.

should be offered to patients aged >70 years.^{7,15} In this analysis, DT-LVAD confers an average life expectancy of 3.6 years among patients aged >70 years (compared with 4.4 years for 50-year-old patients) with an ICER of \$225,000 per QALY gained relative to OHT.

Transplant Wait Time

Median wait time for heart transplant is 5.6 months, with significant variability depending on region and patient characteristics including blood type, size, and allo-antibody sensitization. To assess the sensitivity of transplant wait-list time, we varied the median wait time from 0 to 24 months (Figure 4). A projected life expectancy of 13.8 years conferred by immediate OHT decreases to 4.3 years given a median wait-list time of 24

months. The cost-effectiveness of OHT remains relatively constant because both life expectancy and lifetime costs decrease proportionately with longer waits. If the expected wait for OHT is <1 month, IDMT is preferred to BTT-LVAD while awaiting OHT. For any wait >1 month, BTT-LVAD generates the longest life expectancy. The cost-effectiveness of BTT-LVAD (relative to OHT only) improves as the wait-list time increases because the comparator strategy of IDMT followed by OHT worsens. For example, with a median transplant wait-list time of 24 months, BTT-LVAD costs \$150,000 per QALY gained.

Medical Therapy Mortality

We examined how varying survival of patients on IDMT might influence health outcomes (Figure 4). In our base-case

analysis, the monthly probability of death for OHT-eligible IDMT patients was 0.074. Decreasing this probability by half increases the life expectancy with OHT from 8.5 to 10.8 years. As one might expect, the cost-effectiveness of OHT or LVAD implantation worsens as IDMT survival improves, because the baseline strategy of IDMT seems more favorable. With an average life expectancy on IDMT of 2.5 years—sufficient time for most patients to receive OHT—the ICER for BTT-LVAD exceeded \$500 000 per QALY gained.

Complication Rates

Our state-transition model incorporated clinically relevant postprocedural complications for the life of the patient. Hypothetically, if LVAD-specific and OHT-specific complications were eliminated completely, cost-effectiveness would improve substantially. OHT in patients with a 5.6-month median wait-list time would cost only \$56 000 per QALY gained, BTT-LVAD would cost \$128 000 per QALY gained, and DT-LVAD would cost ≈\$100 000 per QALY gained. This suggests that that future improvements in LVAD implantation and management of complications could make DT-LVAD a viable alternative to heart transplantation.

Discussion

Our analysis adds to the growing body of evidence comparing clinical outcomes and costs of treatment for end-stage heart failure. Our projected survival rates and freedom from complications closely match values reported by INTERMACS for LVADs through 4 years postimplantation and by ISHLT for heart transplants through 7 years postsurgery. Because many clinical trials and observational studies track patients for a limited time, a comprehensive model such as the one we have developed can offer insights about long-term survival and health benefits of different therapies.

Our results suggest that OHT significantly improves life expectancy and costs <\$100 000 per QALY gained, a threshold often considered cost effective for the United States.⁴³ Although the wait-list time influences survival and lifetime costs, OHT remains more cost effective than DT-LVAD in transplant-eligible patients, across a wide range of assumptions. We recognize, however, that certain OHT-eligible patients may experience precipitous decline in clinical condition and may require BTT-LVAD. Although this strategy does not meet conventional cost-effectiveness thresholds under our base-case assumptions, it offers a substantial gain in life expectancy compared with IDMT while awaiting OHT. With a longer transplant wait-list time, decreased index hospitalization costs, or reduced LVAD complication rates, the cost-effectiveness of BTT-LVAD falls <\$150 000 per QALY gained.

The impact of DT-LVAD as a life-prolonging modality in critically ill patients who have no other option should be emphasized. The cost-effectiveness of this therapy has improved dramatically since a 2004 analysis based on the REMATCH trial data reported an ICER of \$802 700.⁴⁵ We expect that as survival and quality of life continue to improve and as adverse events, lengths of stay, device costs, and need for readmission decrease, that cost-effectiveness of this strategy will continue to improve. Although a patient's age impacts overall life expectancy with an LVAD or OHT, increasing age

alone does not impact the relative ranking of each strategy in terms of cost-effectiveness.

One challenge in studying a population with end-stage heart failure is its inherent heterogeneity. Prior studies have demonstrated that cost-effectiveness is not an inherent property of any particular therapy but depends on the patient population in which the therapy is used.⁴⁶ Accordingly, it is important to identify subgroups that will derive benefit based on appropriate, evidence-based selection of patients. To obtain appropriate survival estimates, we separated patients with stage D heart failure based on transplant eligibility. Patients who were OHT ineligible could only receive DT-LVAD as clinical guidelines dictate. In contrast, survival estimates for OHT-eligible patients were in accordance with status 1A or 1B patients who did not receive an LVAD.⁴⁵ These are clearly different subgroups with projected life expectancies that differ by 30% to 50%. In addition, OHT-eligible patients may need to move to DT-LVAD as occasionally occurs in clinical practice. The cost-effectiveness of LVAD as DT or BTT may worsen as survival on medical therapy alone improves.

Our cost-effectiveness estimates of DT-LVAD differ slightly from those reported by Rogers et al,⁷ in part because we accounted for the decrement in utility from complications, stratified patients based on OHT-eligibility, and applied more recent INTERMACS data in which LVAD survival is improved. We found LVAD as BTT to be more cost effective than reported by Moreno et al²⁸ primarily because we assumed a lower survival rate in OHT-eligible IDMT patients by excluding from the analysis IDMT patients who subsequently underwent LVAD implantation.

Our analysis builds on prior studies through our inclusion of commonly tracked medical complications after LVAD implantation and OHT and their associated costs. If such costs were ignored, the cost-effectiveness of both strategies improved by ≈40%, highlighting the importance of including medical complications when evaluating relative cost-effectiveness. It also suggests that as the field continues to mature and outcomes improve, that cost-effectiveness should also improve.

A limitation of our study stems from the paucity of cost data associated with different health states in our model. Although our cost assumptions were based on published estimates, the exact patient population may differ, resulting in over- or underestimates. We estimated quality-of-life factors for each complication state based on published estimates that may include other patient populations. Future studies should examine the costs and utilities associated with each complication state. Mortality rates were extrapolated beyond available registry data for LVAD and transplant patients, which could be revised as additional data become available. Finally, our state-transition model included the most common tracked complications associated with LVADs or OHT, but the model simplified the complex progression of stage D heart failure.

In conclusion, our study demonstrates that heart transplantation results in improved survival and is a cost-effective strategy for most transplant-eligible patients with inotrope-dependent stage D heart failure, compared with medical therapy alone. However, if the anticipated wait-list time exceeds 1 month, BTT-LVAD results in greater life expectancy for patients awaiting OHT than medical therapy alone.

Given national average transplant wait times for status 1A and 1B patients, the cost-effectiveness of BTT-LVAD exceeds \$225 000 per QALY gained, but improves substantially with longer expected transplant wait times. In patients ineligible for transplantation, DT-LVAD substantially improves survival compared with medical therapy, although advances in medical complication rates or implantation costs must improve to render it as cost effective as other medical technologies.

Disclosures

Dr Mangi has received speaking fees and consulting fees from Thoratec Corporation.

References

- Jessup M, Brozena S. Heart failure. *N Engl J Med*. 2003;348:2007–2018.
- Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB, Bravata DM, Dai S, Ford ES, Fox CS, Franco S, Fullerton HJ, Gillespie C, Hailpern SM, Heit JA, Howard VJ, Huffman MD, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Magid D, Marcus GM, Marelli A, Matchar DB, McGuire DK, Mohler ER, Moy CS, Mussolino ME, Nichol G, Paynter NP, Schreiner PJ, Sorlie PD, Stein J, Turan TN, Virani SS, Wong ND, Woo D, Turner MB; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics—2013 update: a report from the American Heart Association. *Circulation*. 2013;127:e6–e245.
- Ho KK, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: the Framingham Study. *J Am Coll Cardiol*. 1993;22(4 suppl A):6A–13A.
- Petersen JW, Felker GM. Inotropes in the management of acute heart failure. *Crit Care Med*. 2008;36(1 suppl):S106–S111.
- American Heart Association. Advanced heart failure. 2013. http://www.heart.org/HEARTORG/Conditions/HeartFailure/Advanced-Heart-Failure_UCM_441925_Article.jsp# Accessed February 3, 2014.
- Rose EA, Gelijns AC, Moskowitz AJ, Heitjan DF, Stevenson LW, Dembitsky W, Long JW, Ascheim DD, Tierney AR, Levitan RG, Watson JT, Meier P, Ronan NS, Shapiro PA, Lazar RM, Miller LW, Gupta L, Frazier OH, Desvigne-Nickens P, Oz MC, Poirier VL; Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH) Study Group. Long-term use of a left ventricular assist device for end-stage heart failure. *N Engl J Med*. 2001;345:1435–1443.
- Rogers JG, Bostic RR, Tong KB, Adamson R, Russo M, Slaughter MS. Cost-effectiveness analysis of continuous-flow left ventricular assist devices as destination therapy. *Circ Heart Fail*. 2012;5:10–16.
- Rogers JG, Butler J, Lansman SL, Gass A, Portner PM, Pasque MK, Pierson RN 3rd; INTRIPID Investigators. Chronic mechanical circulatory support for inotrope-dependent heart failure patients who are not transplant candidates: results of the INTRIPID Trial. *J Am Coll Cardiol*. 2007;50:741–747.
- Mulloy DP, Bhamidipati CM, Stone ML, Ailawadi G, Kron IL, Kern JA. Orthotopic heart transplant versus left ventricular assist device: a national comparison of cost and survival. *J Thorac Cardiovasc Surg*. 2013;145:566–573; discussion 573.
- Stehlik J, Edwards LB, Kucheryavaya AY, Benden C, Christie JD, Dipchand AI, Dobbels F, Kirk R, Rahmel AO, Hertz MI; International Society of Heart and Lung Transplantation. The Registry of the International Society for Heart and Lung Transplantation: 29th official adult heart transplant report—2012. *J Heart Lung Transplant*. 2012;31:1052–1064.
- Russo MJ, Hong KN, Davies RR, Chen JM, Sorabella RA, Ascheim DD, Williams MR, Gelijns AC, Stewart AS, Argenziano M, Naka Y. Posttransplant survival is not diminished in heart transplant recipients bridged with implantable left ventricular assist devices. *J Thorac Cardiovasc Surg*. 2009;138:1425–1432.e1.
- Colvin-Adams M, Valapour M, Hertz M, Heubner B, Paulson K, Dhungel V, Skeans MA, Edwards L, Ghimire V, Waller C, Cherikh WS, Kasiske BL, Snyder JJ, Israni AK. Lung and heart allocation in the United States. *Am J Transplant*. 2012;12:3213–3234.
- Stehlik J, Edwards LB, Rowe A, Philibin K, Williamson J, Kirklin JK, Taylor DO, Hertz MI. ISHLT International Registry for Heart and Lung Transplantation—three decades of scientific contributions. *Transplant Rev (Orlando)*. 2013;27:38–42.
- Slaughter MS, Rogers JG, Milano CA, Russell SD, Conte JV, Feldman D, Sun B, Tatroles AJ, Delgado RM 3rd, Long JW, Wozniak TC, Ghumman W, Farrar DJ, Frazier OH; HeartMate II Investigators. Advanced heart failure treated with continuous-flow left ventricular assist device. *N Engl J Med*. 2009;361:2241–2251.
- Kirklin JK, Naftel DC, Kormos RL, Stevenson LW, Pagani FD, Miller MA, Timothy Baldwin J, Young JB. Fifth INTERMACS annual report: risk factor analysis from more than 6,000 mechanical circulatory support patients. *J Heart Lung Transplant*. 2013;32:141–156.
- Williams ML, Trivedi JR, McCants KC, Prabhu SD, Birks EJ, Oliver L, Slaughter MS. Heart transplant vs left ventricular assist device in heart transplant-eligible patients. *Ann Thorac Surg*. 2011;91:1330–1333; discussion 1333.
- Healy AH, Baird BC, Drakos SG, Stehlik J, Selzman CH. Impact of ventricular assist device complications on posttransplant survival: an analysis of the United network of organ sharing database. *Ann Thorac Surg*. 2013;95:870–875.
- Kamdar F, John R, Eckman P, Colvin-Adams M, Shumway SJ, Liao K. Postcardiac transplant survival in the current era in patients receiving continuous-flow left ventricular assist devices. *J Thorac Cardiovasc Surg*. 2013;145:575–581.
- Miller LW, Guglin M. Patient selection for ventricular assist devices: a moving target. *J Am Coll Cardiol*. 2013;61:1209–1221.
- Arias E. United States life tables, 2008. *Natl Vital Stat Report*. 2012;61:1–64.
- Singh TP, Almond CS, Taylor DO, Graham DA. Decline in heart transplant wait list mortality in the United States following broader regional sharing of donor hearts. *Circ Heart Fail*. 2012;5:249–258.
- Russo MJ, Gelijns AC, Stevenson LW, Sampat B, Aaronson KD, Renlund DG, Ascheim DD, Hong KN, Oz MC, Moskowitz AJ, Rose EA, Miller LW; REMATCH Investigators. The cost of medical management in advanced heart failure during the final two years of life. *J Card Fail*. 2008;14:651–658.
- Sharples LD, Dyer M, Cafferty F, Demiris N, Freeman C, Banner NR, Large SR, Tsui S, Caine N, Buxton M. Cost-effectiveness of ventricular assist device use in the United Kingdom: results from the evaluation of ventricular assist device programme in the UK (EVAD-UK). *J Heart Lung Transplant*. 2006;25:1336–1343.
- Slaughter MS, Bostic R, Tong K, Russo M, Rogers JG. Temporal changes in hospital costs for left ventricular assist device implantation. *J Card Surg*. 2011;26:535–541.
- Post PN, Stiggelbout AM, Wakker PP. The utility of health states after stroke: a systematic review of the literature. *Stroke*. 2001;32:1425–1429.
- Moskowitz AJ, Rose EA, Gelijns AC. The cost of long-term LVAD implantation. *Ann Thorac Surg*. 2001;71(3 suppl):S195–S198; discussion S203.
- Digiorgi PL, Reel MS, Thornton B, Burton E, Naka Y, Oz MC. Heart transplant and left ventricular assist device costs. *J Heart Lung Transplant*. 2005;24:200–204.
- Moreno SG, Novielli N, Cooper NJ. Cost-effectiveness of the implantable HeartMate II left ventricular assist device for patients awaiting heart transplantation. *J Heart Lung Transplant*. 2012;31:450–458.
- Kirklin JK, Naftel DC, Kormos RL, Stevenson LW, Pagani FD, Miller MA, Baldwin JT, Young JB. The Fourth INTERMACS Annual Report: 4,000 implants and counting. *J Heart Lung Transplant*. 2012;31:117–126.
- Liem YS, Bosch JL, Hunink MG. Preference-based quality of life of patients on renal replacement therapy: a systematic review and meta-analysis. *Value Health*. 2008;11:733–741.
- Aggarwal A, Pant R, Kumar S, Sharma P, Gallagher C, Tatroles AJ, Pappas PS, Bhat G. Incidence and management of gastrointestinal bleeding with continuous flow assist devices. *Ann Thorac Surg*. 2012;93:1534–1540.
- John R, Kamdar F, Eckman P, Colvin-Adams M, Boyle A, Shumway S, Joyce L, Liao K. Lessons learned from experience with over 100 consecutive HeartMate II left ventricular assist devices. *Ann Thorac Surg*. 2011;92:1593–1599; discussion 1599.
- Demirozu ZT, Radovancevic R, Hochman LF, Gregoric ID, Letsou GV, Kar B, Bogaev RC, Frazier OH. Arteriovenous malformation and gastrointestinal bleeding in patients with the HeartMate II left ventricular assist device. *J Heart Lung Transplant*. 2011;30:849–853.
- Earle CC, Chapman RH, Baker CS, Bell CM, Stone PW, Sandberg EA, Neumann PJ. Systematic overview of cost-utility assessments in oncology. *J Clin Oncol*. 2000;18:3302–3317.
- Pickard AS, Wilke CT, Lin HW, Lloyd A. Health utilities using the EQ-5D in studies of cancer. *Pharmacoeconomics*. 2007;25:365–384.
- Engel-Nitz NM, Sander SD, Harley C, Rey GG, Shah H. Costs and outcomes of noncardioembolic ischemic stroke in a managed care population. *Vasc Health Risk Manag*. 2010;6:905–913.

37. Whelan CT, Chen C, Kaboli P, Siddique J, Prochaska M, Meltzer DO. Upper versus lower gastrointestinal bleeding: a direct comparison of clinical presentation, outcomes, and resource utilization. *J Hosp Med.* 2010;5:141–147.
38. United States Renal Data System. *Annual Data Report—Volume Three. Reference Tables on End-Stage Renal Disease: Section H—Mortality & Causes of Death.* Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2012.
39. Yabroff KR, Lamont EB, Mariotto A, Warren JL, Topor M, Meekins A, Brown ML. Cost of care for elderly cancer patients in the United States. *J Natl Cancer Inst.* 2008;100:630–641.
40. Moazami N, Milano CA, John R, Sun B, Adamson RM, Pagani FD, Smedira N, Slaughter MS, Farrar DJ, Frazier OH; HeartMate II Investigators. Pump replacement for left ventricular assist device failure can be done safely and is associated with low mortality. *Ann Thorac Surg.* 2013;95:500–505.
41. Gold M, Siegel J, Russell L, Weinstein M. *Cost-Effectiveness in Health and Medicine.* New York, NY: Oxford University Press; 1996.
42. Bureau of Labor Statistics. Overview of BLS statistics on inflation and prices. 2013. <http://www.bls.gov/bls/inflation.htm>. Accessed June 6, 2013.
43. Braithwaite RS, Meltzer DO, King JT Jr, Leslie D, Roberts MS. What does the value of modern medicine say about the \$50,000 per quality-adjusted life-year decision rule? *Med Care.* 2008;46:349–356.
44. Atluri P, Goldstone AB, Kobrin DM, Cohen JE, MacArthur JW, Howard JL, Jessup ML, Rame JE, Acker MA, Woo YJ. Ventricular assist device implant in the elderly is associated with increased, but respectable risk: a multi-institutional study. *Ann Thorac Surg.* 2013;96:141–147.
45. Slaughter MS, Rogers JG. Editorial Commentary: Determining the cost-effectiveness of mechanical circulatory support. *J Heart Lung Transplant.* 2012;31:448–449.
46. Sanders GD, Hlatky MA, Owens DK. Cost-effectiveness of implantable cardioverter-defibrillators. *N Engl J Med.* 2005;353:1471–1480.

CLINICAL PERSPECTIVE

Congestive heart failure exerts a significant epidemiological burden on our society. Therapies for advanced heart failure have evolved rapidly during the last decade with significant improvements in survival and outcomes, resulting in robust diffusion of these therapies to the heart failure population. In a social, political, and economic climate where discussions on healthcare expenditures dominate the conversation, we wished to gain greater clarity into the real-world contemporary outcomes and costs of left ventricular assist device (LVAD) implantation and cardiac transplantation as compared with inotropic medical therapy. We developed a novel decision-analytic model, which not only accounts for survival, but also is the first to account for condition-specific complications for patients receiving inotropes, those undergoing LVAD for destination therapy, LVAD as bridge to transplant, and cardiac transplantation. Cost estimates were obtained from a major academic hospital and other published sources. Our results suggest that contemporary cardiac transplantation and LVAD implantation exert significant beneficial influence on survival rates, longevity, and quality of life. Costs for cardiac transplantation have continued to decrease, and it now approaches the threshold for cost-effectiveness in the United States. LVAD therapy is still expensive but costs significantly less than it did a decade ago and offers dramatic improvements in survival and quality of life which continue to make it an attractive therapeutic option. We can expect that careful attention to patient selection, thoughtful and more efficient use of transplant wait lists, and continued control of complications requiring hospital readmission will render all therapies more cost effective in the future.